Consistently ranked as one of the leading causes of death around the world, malaria doesn’t have an effective vaccine yet. But researchers have invented a promising new blueprint for one — with properties akin to the novel RNA-based vaccine for COVID-19.
  • disrooter@lemmy.ml
    25·
    4 years ago

    Here in Italy we have thousands of doctors who coordinate in Whatsapp chats and Facebook groups and have treated tens of thousands of people. Would you like to join those groups and accuse them of being fake and that Sars-Cov2 infection cannot be cured?

    • Dessalines@lemmy.ml
      32·
      4 years ago

      Yes it can be cured. With a vaccine. that’s why many different countries are pouring millions of dollars into this effort. Are you saying you don’t believe these vaccines are actually effective?

      • disrooter@lemmy.ml
        15·
        4 years ago

        No, you didn’t understand what I said. I better explained my thought in my reply to you. Next time ask for clarification before deleting comments with big assumptions by you.

        Also man, saying Sars-Cov2 can’t be cured is bold. Are you serious about this or are you provocative? Be caureful, someone could misinterpret what you wrote. 😂

      • disrooter@lemmy.ml
        16·
        4 years ago

        This is a study published in Science which among other things states that when Sars-Cov2 goes to the endemic phase there will be no need for the vaccine and that social distancing is probably counterproductive on this:

        “The model code provides a flexible scaffolding for studying alternative vaccination scenarios. Notably, the model predicts that once the endemic state is reached, mass vaccination may no longer be necessary to save lives.”

        “Should the vaccine cause a major reduction in transmission, it might be important to consider strategies that target delivery to older individuals for whom infection can cause higher morbidity and mortality, while allowing natural immunity and transmission to be maintained in younger individuals.”

        “Additionally, during the transition to endemicity, we need to consider how the immune efficacies depend on primary and secondary infections across ages and how responses differ between vaccination and natural infection.”

        “The key result from our model framework that explicitly recognizes that functional immunity to reinfection, disease, and shedding are different is that, in contrast with infections that are severe in childhood, SARS-CoV-2 could join the ranks of mild, cold-causing endemic HCoVs in the long run.”

        “The transition from epidemic to endemic dynamics is associated with a shift in the age distribution of primary infections to lower age groups. This transition may take anywhere from a few years to a few decades, depending on how quickly the pathogen spreads. The rate of spread, measured by R0, is determined by a combination of viral properties and the frequency of social contacts and may therefore be reduced by social distancing.”

        https://science.sciencemag.org/content/371/6530/741